Publications

Bruxelles Woluwe

Selected publications

  1. Elens L., van Gelder T., Hesselink D.A., Haufroid V., van Schaik R.H.
    CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.
    Pharmacogenomics (2013), 14: 47-62.
  2. de Graan A.J., Elens L., Sprowl J.A., Sparreboom A., Friberg L.E., Van der Holt B., de Raaf P.J., de Bruijn P., Engels F.K., Eskens F.A., Wiemer E.A., Verweij J., Mathijssen R.H., Van Schaik R.H.
    CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
    Clin Cancer Res. (2013), 19: 3316-24.
  3. Elens L., Bouamar R., Hesselink D.A., Haufroid V., Van der Heiden I.P., Van Gelder T., Van Schaik R.H.
    A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Clin Chem. (2011), 57: 1574-83.
  4. Elens L., Tyteca D., Panin N., Courtoy P., Lison D., Demoulin J-B., Haufroid V.
    Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition.
    Pharmacogenet Genomics (2011), 21: 884-93.
  5. Elens L., Vandercam B., Yombi J-C., Lison D., Wallemacq P., Haufroid V.
    Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
    Pharmacogenomics (2010), 11: 1223-34.